A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Summary

The Stage 2 of this phase 2 study is an open-label, single-arm study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.

Timeline

Start

2023-05-10

Primary completion

2023-11-29

Completion

2024-01-05

Outcome

Met primary endpoint

registry analysis (other test); CBL-514 up to 320mg; p <0.00001; Paired t-test NCT05836779 ↗

release “CBL-0201EFP Phase 2-stage 2已於2024年1月完成試驗，並於2024年4月取得臨床統計結果，其主要療效指標與次要療效指標在ITT與PP皆達到臨床及統計上顯著有效意義” caliwaybiopharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CBL-514	Unknown	320 mg	Subcutaneous

Indications